Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
Condition(s):Heart FailureLast Updated:May 18, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Heart FailureLast Updated:May 18, 2023Completed
Condition(s):Hemodialysis Complication; Heart FailureLast Updated:October 6, 2020Unknown status
Condition(s):Hypertension Complicated; Hypertrophy, Left Ventricular; Blood PressureLast Updated:April 11, 2018Completed
Condition(s):Breast Cancer; Neoplasm, Breast; Breast Diseases; Antihypertensive Agents; Sacubitril/Valsartan; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Molecular Mechanisms of Pharmacological Action; Heart Failure; Cardiac Toxicity; Cancer, Therapy-Related; Cancer Therapy-Related Cardiac Dysfunction; CardiotoxicityLast Updated:July 19, 2022Not yet recruiting
Condition(s):Heart FailureLast Updated:June 24, 2022Completed
Condition(s):Heart Failure; Heart DysfunctionLast Updated:May 10, 2023Recruiting
Condition(s):Sacubitril/Valsartan; Hypertension; ObesityLast Updated:August 8, 2023Recruiting
Condition(s):Hypertension;NephropathyLast Updated:July 20, 2018Not yet recruiting
Condition(s):Heart Failure With Moderately Reduced Ejection FractionLast Updated:August 19, 2022Not yet recruiting
Condition(s):Essential HypertensionLast Updated:November 8, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.